Video

Dr. He Discusses Potential Therapeutic Uses for GTF2I L424+ Thymic Cancers

Yongfeng He, PhD, discusses how the presence of the GTF2I L424H mutation in thymic epithelial cells induced thymic tumors in mouse models.

Yongfeng He, PhD, is an instructor of cancer biology in medicine at Weill Cornell Medicine in New York, New York.

He, along with Giuseppe Gianccone, MD, PhD, professor of medicine and associate director of clinical research at the Sandra and Edward Meyer Cancer Center at Weill Cornell, discovered that the presence of the GTF2I L424H mutation in thymic epithelial cells induced thymic tumors in mouse models. The mouse tumors shared many molecular characteristics with type B1 and B2 human thymic tumors.

He said that GTF2I L424H is a transcription factor so it is unlikely to be a therapeutic target. However, this discovery may be the first step in developing a systemic treatment for patients with thymic cancers.

Related Videos
Timothy Gershon, MD, PhD
Jordan Hansford, MD
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Shubham Pant, MD, MBBS
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University
Brett L. Ecker, MD